Immix Biopharma Inc publishes presentation highlighting leadership in relapsed and refractory AL Amyloidosis and promising NXC201 clinical data

Reuters10-09
<a href="https://laohu8.com/S/IMMX">Immix Biopharma</a> Inc publishes presentation highlighting leadership in relapsed and refractory AL Amyloidosis and promising NXC201 clinical data

Immix Biopharma Inc. has released a presentation highlighting its progress and market position in the treatment of relapsed/refractory AL Amyloidosis. The company reports that its investigational therapy, NXC-201, has demonstrated a 70% complete response rate in clinical trials, significantly outperforming the current standard of care, which shows a 0-10% complete response rate. The NEXICART-2 clinical trial for NXC-201 is currently over 50% enrolled, with plans for a Biologics License Application (BLA) submission in the first half of 2026 and a commercial launch anticipated in late 2026. Immix Biopharma notes a market prevalence of 34,600 patients for AL Amyloidosis, with no FDA-approved drugs currently available for this indication. The company is preparing for commercial launch through 18 high-prescribing clinical trial sites and emphasizes its experienced management and clinical team. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on October 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment